Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Return on Invested Capital (ROIC)
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | (5,356,995) | (5,673,614) | (10,550,503) | (2,001,620) | (3,502,617) | |
| Invested capital2 | 80,268,300) | 91,098,773) | 103,552,681) | 111,246,522) | 127,501,981) | |
| Performance Ratio | ||||||
| ROIC3 | -6.67% | -6.23% | -10.19% | -1.80% | -2.75% | |
| Benchmarks | ||||||
| ROIC, Competitors4 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2019 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × -5,356,995 ÷ 80,268,300 = -6.67%
4 Click competitor name to see calculations.
An analysis of the return on invested capital from 2015 to 2019 reveals a consistent inability to generate positive operating returns. Throughout the period, the return on invested capital remained negative, indicating that operating profits were insufficient to cover the costs associated with the invested capital base.
- Net Operating Profit After Taxes (NOPAT)
- NOPAT remained negative for the entire five-year duration. Although a moderate improvement occurred in 2016, a significant deterioration was observed in 2017, where losses reached 10.55 billion US dollars. While losses narrowed in 2018 and 2019, they remained substantial, ending the period at approximately 5.36 billion US dollars.
- Invested Capital
- A steady and continuous decline in invested capital is observed. The capital base decreased from 127.50 billion US dollars in 2015 to 80.27 billion US dollars by 2019. This represents a consistent reduction in the total capital employed in the business over the analyzed timeframe.
- Return on Invested Capital (ROIC) Trends
- The ROIC exhibited volatility within a negative range. The most significant decline occurred in 2017, with ROIC falling to -10.19%, directly correlating with the peak in NOPAT losses. Despite the continuous reduction in invested capital, the persistence of negative operating profits prevented the ROIC from returning to positive territory, resulting in a final value of -6.67% in 2019.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Decomposition of ROIC
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
The Return on Invested Capital (ROIC) remained consistently negative from 2015 through 2019, reflecting a period of significant financial volatility. The overall trajectory of the return was primarily dictated by deeply negative operating margins, which offset the steady improvements observed in capital efficiency.
- Operating Profit Margin (OPM)
- The operating profit margin exhibited extreme volatility and remained in negative territory throughout the analyzed period. A critical downturn occurred in 2017, when the margin reached its lowest point at -58.34%. While a recovery trend followed, with the margin improving to -27.74% by 2019, the results indicate a persistent inability to generate operating profits from revenue.
- Turnover of Capital (TO)
- A consistent and linear upward trend is observed in the turnover of capital. The ratio improved every year, rising from 0.12 in 2015 to 0.20 in 2019. This indicates a progressive increase in the efficiency with which the invested capital was utilized to generate sales.
- Effective Cash Tax Rate (CTR) Impact
- The tax component of the ROIC decomposition remained static at 100.00% for the entire five-year duration. This stability suggests that the effective cash tax rate had no reductive impact on the return, a condition typically associated with sustained operating losses that offset tax liabilities.
- Return on Invested Capital (ROIC) Synthesis
- The ROIC mirrored the volatility of the operating profit margin, plunging to -10.19% in 2017 in tandem with the margin collapse. Although the increase in capital turnover provided a positive counterbalance, it was insufficient to move the ROIC into positive territory. The period concluded with an ROIC of -6.67% in 2019, indicating that despite improved capital efficiency and a recovering operating margin, the return on invested capital remained negative.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Operating Profit Margin (OPM)
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | (5,356,995) | (5,673,614) | (10,550,503) | (2,001,620) | (3,502,617) | |
| Add: Cash operating taxes2 | 897,358) | (398,902) | 1,237,785) | 294,697) | 398,183) | |
| Net operating profit before taxes (NOPBT) | (4,459,638) | (6,072,516) | (9,312,718) | (1,706,923) | (3,104,433) | |
| Net revenues | 16,088,900) | 15,787,400) | 15,940,700) | 14,570,600) | 15,071,000) | |
| Add: Increase (decrease) in deferred revenue | (9,500) | (1,800) | 22,200) | (2,500) | (8,100) | |
| Adjusted net revenues | 16,079,400) | 15,785,600) | 15,962,900) | 14,568,100) | 15,062,900) | |
| Profitability Ratio | ||||||
| OPM3 | -27.74% | -38.47% | -58.34% | -11.72% | -20.61% | |
| Benchmarks | ||||||
| OPM, Competitors4 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2019 Calculation
OPM = 100 × NOPBT ÷ Adjusted net revenues
= 100 × -4,459,638 ÷ 16,079,400 = -27.74%
4 Click competitor name to see calculations.
The financial performance between 2015 and 2019 is characterized by persistent operating losses despite a relatively stable revenue base. The operational efficiency, as measured by the operating profit margin, remained negative throughout the five-year period, exhibiting significant volatility particularly during the 2017 fiscal year.
- Net Operating Profit Before Taxes (NOPBT)
- Operating losses were present across all reported years. While the loss narrowed from -3.1 billion US$ in 2015 to -1.7 billion US$ in 2016, a substantial increase in losses occurred in 2017, reaching -9.3 billion US$. Following this peak, a recovery trend is evident, with losses reducing to -6.1 billion US$ in 2018 and -4.5 billion US$ in 2019.
- Adjusted Net Revenues
- Revenue levels demonstrated consistency, fluctuating within a narrow band between 14.6 billion US$ and 16.1 billion US$. This stability indicates that the volatility in operating profit was not driven by significant shifts in top-line performance, but rather by costs or adjustments affecting the operational result.
- Operating Profit Margin (OPM)
- The OPM reflects the high volatility of the NOPBT relative to steady revenues. The margin improved from -20.61% in 2015 to -11.72% in 2016 before dropping sharply to -58.34% in 2017. A progressive recovery followed, with the margin improving to -38.47% in 2018 and -27.74% in 2019. Despite the positive trajectory since 2017, the company remained unable to reach a break-even operating margin by the end of the observed period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Turnover of Capital (TO)
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net revenues | 16,088,900) | 15,787,400) | 15,940,700) | 14,570,600) | 15,071,000) | |
| Add: Increase (decrease) in deferred revenue | (9,500) | (1,800) | 22,200) | (2,500) | (8,100) | |
| Adjusted net revenues | 16,079,400) | 15,785,600) | 15,962,900) | 14,568,100) | 15,062,900) | |
| Invested capital1 | 80,268,300) | 91,098,773) | 103,552,681) | 111,246,522) | 127,501,981) | |
| Efficiency Ratio | ||||||
| TO2 | 0.20 | 0.17 | 0.15 | 0.13 | 0.12 | |
| Benchmarks | ||||||
| TO, Competitors3 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 Invested capital. See details »
2 2019 Calculation
TO = Adjusted net revenues ÷ Invested capital
= 16,079,400 ÷ 80,268,300 = 0.20
3 Click competitor name to see calculations.
The analysis of capital efficiency from 2015 to 2019 reveals a consistent and progressive improvement in the turnover of capital ratio, which increased from 0.12 to 0.20 over the five-year period.
- Adjusted Net Revenues
- Revenue levels remained relatively stable throughout the analyzed period. After a slight decrease in 2016, revenues trended upward, moving from 15.06 billion US$ in 2015 to 16.08 billion US$ by 2019. The lack of aggressive top-line growth suggests that the improvement in capital turnover was not driven by significant expansion in sales volume.
- Invested Capital
- A significant and continuous downward trend is observed in invested capital. The capital base contracted from 127.50 billion US$ in 2015 to 80.27 billion US$ in 2019. This represents a substantial reduction in the assets employed to generate revenue, indicating a strategic reduction in the capital intensity of the business operations.
- Turnover of Capital (TO)
- The turnover of capital ratio demonstrated a steady linear increase, rising each year from 0.12 in 2015 to 0.20 in 2019. Because revenues remained largely flat while the invested capital base decreased significantly, the increase in the ratio is primarily attributable to the reduction in the denominator. This indicates a marked improvement in asset utilization efficiency, as the organization generated a similar level of revenue with substantially fewer invested resources.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Effective Cash Tax Rate (CTR)
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | (5,356,995) | (5,673,614) | (10,550,503) | (2,001,620) | (3,502,617) | |
| Add: Cash operating taxes2 | 897,358) | (398,902) | 1,237,785) | 294,697) | 398,183) | |
| Net operating profit before taxes (NOPBT) | (4,459,638) | (6,072,516) | (9,312,718) | (1,706,923) | (3,104,433) | |
| Tax Rate | ||||||
| CTR3 | — | — | — | — | — | |
| Benchmarks | ||||||
| CTR, Competitors4 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2019 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × 897,358 ÷ -4,459,638 = —
4 Click competitor name to see calculations.
The financial profile from 2015 to 2019 is characterized by consistent negative net operating profit before taxes (NOPBT) coupled with volatile cash tax payments. This divergence indicates a significant disconnect between accounting-based operating performance and the actual cash outflows required for tax obligations.
- Net Operating Profit Before Taxes (NOPBT)
- A persistent state of operating loss is observed throughout the five-year period. The losses peaked in 2017 at approximately 9.31 billion US dollars, following a period of relative stability between 2015 and 2016. Although NOPBT began to recover toward the end of the period, it remained substantially negative, ending at 4.46 billion US dollars in 2019.
- Cash Operating Taxes
- Cash tax expenditures exhibit high volatility and do not correlate linearly with operating profit. Despite negative NOPBT, cash taxes remained positive in four of the five years analyzed, peaking in 2017 at 1.24 billion US dollars. A notable anomaly occurred in 2018, where cash operating taxes turned negative to 398.9 million US dollars, suggesting a tax refund or the realization of significant tax credits.
- Effective Cash Tax Rate (CTR) Interpretation
- The calculation of the effective cash tax rate is distorted by the consistently negative NOPBT. In most years, the company experienced positive cash tax outflows despite reporting operational losses, resulting in negative CTR values. This pattern typically suggests that non-deductible accounting expenses or disparate tax regulations across different jurisdictions prevented the operational losses from offsetting cash tax liabilities. The 2018 period represents the only instance where both NOPBT and cash taxes were negative, creating a mathematically positive but atypical CTR.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?